SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 24, 2002; DOI 10.1182/blood-2002-02-0513. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-02-0513v1 100/6/2123    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Krackhardt, A. M. Articles by Gribben, J. G. Search for Related Content PubMed PubMed Citation Articles by Krackhardt, A. M. Articles by Gribben, J. G. Related Collections Immunotherapy Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2002, Vol. 100, No. 6, pp. 2123-2131 IMMUNOBIOLOGY Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX Angela M. Krackhardt, Mathias Witzens, Sabine Harig, F. Stephen Hodi, A. Jason Zauls, Morgan Chessia, Patrick Barrett, and John G. Gribben From the Department of Adult Oncology, Dana Farber Cancer Institute; and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; both of Boston, MA; and Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Universitätsklinikum Benjamin Franklin, Berlin, Germany. Chronic lymphocytic leukemia (CLL) is associated with a variety of immunologic disturbances. Hypogammaglobulinemia and autoimmune phenomena are both often present in this disease. In contrast, humoral or cellular antitumor responses are rarely observed. It has been previously shown that antigens detected in patients with malignant diseases can provide information regarding intracellular molecules engaged in the transformation process and can identify tumor antigens that may be useful for development of immunotherapeutic strategies. Serologic identification by recombinant expression cloning (SEREX) has been demonstrated to be a useful method to detect tumor and tumor-associated antigens in a variety of malignancies. Although this approach is complicated in CLL, we used a modified SEREX approach and identified 14 antigens (KW-1 to KW-14) using this methodology. Several clones showed a restricted expression pattern in normal tissues. Moreover, distinctive expression of splice variants and aberrant gene expression in malignant tissue were detected. In this study, 6 antigens were detected exclusively in patients with CLL. Eight antigens were detected also in lymphoma patients. Healthy donors showed antibody responses against only 3 of the identified antigens. T cells with specific cytotoxicity against peptides derived from the 2 antigens tested could be generated from healthy donors. These findings demonstrate that humoral and cellular immune responses against CLL-associated antigens can be detected. Ongoing experiments investigate their potential for the development of immunotherapeutic strategies. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Wang, M.-X. Guo, H.-M. Hu, Z.-Z. Zhao, H.-L. Qiu, H.-J. Shao, C.-G. Zhu, L. Xue, Y.-B. Shi, and W.-X. Li Human T-cell Leukemia Virus Type 1 Oncoprotein Tax Represses ZNF268 Expression through the cAMP-responsive Element-binding Protein/Activating Transcription Factor Pathway J. Biol. Chem., June 13, 2008; 283(24): 16299 - 16308. [Abstract] [Full Text] [PDF] I. G. Schuster, D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nossner, et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies Blood, October 15, 2007; 110(8): 2931 - 2939. [Abstract] [Full Text] [PDF] A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF] N. BIZZARO, E. TONUTTI, D. VISENTINI, M. G. ALESSIO, S. PLATZGUMMER, G. MOROZZI, A. ANTICO, D. VILLALTA, S. PILLER-RONER, and E. VIGEVANI Antibodies to the Lens and Cornea in Anti-DFS70-Positive Subjects Ann. N.Y. Acad. Sci., June 1, 2007; 1107(1): 174 - 183. [Abstract] [Full Text] [PDF] C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1745 - 1759. [Abstract] [Full Text] [PDF] M.-X. Guo, D. Wang, H.-J. Shao, H.-L. Qiu, L. Xue, Z.-Z. Zhao, C.-G. Zhu, Y.-B. Shi, and W.-X. Li Transcription of Human Zinc Finger ZNF268 Gene Requires an Intragenic Promoter Element J. Biol. Chem., August 25, 2006; 281(34): 24623 - 24636. [Abstract] [Full Text] [PDF] M. Cardelli, F. Marchegiani, L. Cavallone, F. Olivieri, S. Giovagnetti, E. Mugianesi, R. Moresi, R. Lisa, and C. Franceschi A Polymorphism of the YTHDF2 Gene (1p35) Located in an Alu-Rich Genomic Domain Is Associated With Human Longevity. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 547 - 556. [Abstract] [Full Text] [PDF] R. Godal, U. Keilholz, L. Uharek, A. Letsch, A. M. Asemissen, A. Busse, I.-K. Na, E. Thiel, and C. Scheibenbogen Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 Blood, April 15, 2006; 107(8): 3205 - 3211. [Abstract] [Full Text] [PDF] C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells Blood, November 1, 2005; 106(9): 3223 - 3226. [Abstract] [Full Text] [PDF] L. Casciola-Rosen, K. Nagaraju, P. Plotz, K. Wang, S. Levine, E. Gabrielson, A. Corse, and A. Rosen Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy J. Exp. Med., February 22, 2005; 201(4): 591 - 601. [Abstract] [Full Text] [PDF] C. S. Gricks, D. Zahrieh, A. J. Zauls, G. Gorgun, D. Drandi, K. Mauerer, D. Neuberg, and J. G. Gribben Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells Blood, December 15, 2004; 104(13): 4002 - 4009. [Abstract] [Full Text] [PDF] M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben CD40 activation: potential for specific immunotherapy in B-CLL Ann. Onc., June 1, 2004; 15(6): 853 - 857. [Abstract] [Full Text] [PDF] M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells Blood, March 1, 2004; 103(5): 1763 - 1769. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020